SCHEMBL17618596

SCHEMBL17618596

COc1cncc(-c2ccc3c(n2)N(C(=O)Nc2ccccn2)[C@H]2CCN3C2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 4/20 0.41
▸ GSK3B P49841 3/20 0.41
▸ ABL1 P00519 1/20 0.37
▸ NEK2 P51955 1/20 0.36
▸ AKT1 P31749 1/20 0.36
▸ RPS6KA1 Q15418 1/20 0.36
▸ GAA P10253 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ EGFR P00533 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ PIK3CA P42336 2/20 0.35
▸ MTOR P42345 2/20 0.35
▸ F2 P00734 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17618508 0.90 NEK2 (0.44) DYRK1AGSK3BABL1NEK2GAA
SCHEMBL17618562 0.90 PRMT5 (0.39) DYRK1AGSK3BPIK3CAMEN1KMT2A
SCHEMBL17618539 0.88 CNR2 (0.39) DYRK1AGSK3BABL1ALDH1A1MEN1
SCHEMBL17618605 0.88 GSK3B (0.38) DYRK1AGSK3BABL1
SCHEMBL17624238 0.87 PIK3C3 (0.41) DYRK1AGSK3BPIK3CAMTORNPC1
SCHEMBL17618604 0.86 FAAH (0.37) DYRK1AGSK3BMEN1KMT2A
SCHEMBL17618581 0.86 EGFR (0.43) DYRK1AGSK3BGAASMN1; SMN2EGFR
SCHEMBL17618603 0.86 GSK3B (0.40) DYRK1AGSK3BABL1
SCHEMBL17618566 0.86 TRPV1 (0.40) DYRK1AABL1GAAPIK3CASYK
SCHEMBL19365296 0.85 DYRK1A (0.42) DYRK1AGSK3BGAASMN1; SMN2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed
US-9765075-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-09-19 — — US disclosed
US-9765075-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-09-19 — — US disclosed
US-20160083386-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2016-03-24 — — US disclosed
US-20160083386-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2016-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083386-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 DYRK1A 2415/4885GSK3B 2465/4885ABL1 3987/4885
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 DYRK1A 2623/4885GSK3B 1728/4885ABL1 4089/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 DYRK1A 2623/4885GSK3B 1728/4885ABL1 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback